Polypharmacy in the Elderly: A Double-Edged Sword

Purpose: Polypharmacy is a very important geriatric syndrome related to critical health conditions. The purpose of this study is to research the association of polypharmacy with comprehensive geriatric assessment’s (CGA) various parameters which are indicators of health and life quality in older individuals. Material and Methods: 515 older adults admitted to a university hospital were included in this cross-sectional study. Along with CGA, European Quality of Life (EQ-5D) was performed on the participants. Geriatric Depression Scale (GDS) was used to evaluate depressive symptoms. Daily living activities were assessed by using Lawton & Brody index of Instrumental Activities of Daily Living (IADL) and Katz Index of Activities of Daily Living (ADL). The Full Mini-Nutritional Assessment (MNA) questionnaire was performed to evaluate nutritional status. Results: The participants’ mean age was 72.2±6.3 years and 58.6% of them were female. 242 participants using 5 or more drugs were included in the polypharmacy group. The polypharmacy group had lower IADL, MNA, EQ-5D, HGS, and gait speed scores and higher GDS scores compared to those without polypharmacy. According to the correlation analysis results, the number of the medications had a moderate positive correlation with GDS scores and a moderate negative correlation with EQ-5D and MNA. Conclusion: As the number of medications increases; patients tend to have depression, malnutrition, and a decline in functional status. Polypharmacy also impairs the quality of life. It will be wise to address polypharmacy as a crucial health problem, optimize the number of medications and thereby make the health condition better.

[1]  H. Wakabayashi,et al.  Deprescribing Leads to Improved Energy Intake among Hospitalized Older Sarcopenic Adults with Polypharmacy after Stroke , 2022, Nutrients.

[2]  P. Sourtzi,et al.  Sarcopenia and polypharmacy among older adults: A scoping review of the literature. , 2021, Archives of gerontology and geriatrics.

[3]  M. Wehling,et al.  Polypharmacy in older adults: a narrative review of definitions, epidemiology and consequences , 2021, European Geriatric Medicine.

[4]  M. Zeegers,et al.  Multimorbidity and quality of life: Systematic literature review and meta-analysis , 2019, Ageing Research Reviews.

[5]  C. Meisinger,et al.  The Association Between Polypharmacy and Physical Function in Older Adults: a Systematic Review , 2019, Journal of General Internal Medicine.

[6]  K. Johnell,et al.  An update on the clinical consequences of polypharmacy in older adults: a narrative review , 2018, Expert opinion on drug safety.

[7]  I. Kunnamo,et al.  Polypharmacy in older patients with chronic diseases: a cross-sectional analysis of factors associated with excessive polypharmacy , 2018, BMC Family Practice.

[8]  D. Kuh,et al.  Associations Between Polypharmacy and Cognitive and Physical Capability: A British Birth Cohort Study , 2018, Journal of the American Geriatrics Society.

[9]  Gillian E. Caughey,et al.  What is polypharmacy? A systematic review of definitions , 2017, BMC Geriatrics.

[10]  Y. Shiratsuchi,et al.  The relationship between polypharmacy and recovery of activities of daily living among convalescent stroke patients: A propensity score-matched analysis , 2017 .

[11]  A. Majeed,et al.  Current and future perspectives on the management of polypharmacy , 2017, BMC Family Practice.

[12]  H. Yavuzer,et al.  Is Depression a Predictive Factor for Polypharmacy in Elderly , 2016 .

[13]  M. Goldstein,et al.  Health Outcomes Associated with Polypharmacy in Community‐Dwelling Older Adults: A Systematic Review , 2014, Journal of the American Geriatrics Society.

[14]  F. López-Muñoz,et al.  Risk–benefit analysis of antidepressant drug treatment in the elderly , 2014, Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society.

[15]  A. Wollny,et al.  Optimizing polypharmacy among elderly hospital patients with chronic diseases—study protocol of the cluster randomized controlled POLITE-RCT trial , 2014, Implementation Science.

[16]  G. Onder,et al.  Physical performance measures and polypharmacy among hospitalized older adults: Results from the crime study , 2014, The journal of nutrition, health & aging.

[17]  R. Sulkava,et al.  Association of polypharmacy with nutritional status, functional ability and cognitive capacity over a three‐year period in an elderly population , 2011, Pharmacoepidemiology and drug safety.

[18]  Sandrine Andrieu,et al.  Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. , 2011, Journal of the American Medical Directors Association.

[19]  P. Bytzer Dyspepsia as an adverse effect of drugs. , 2010, Best practice & research. Clinical gastroenterology.

[20]  D. Woodwell,et al.  Polypharmacy in nursing home residents in the United States: results of the 2004 National Nursing Home Survey. , 2010, The American journal of geriatric pharmacotherapy.

[21]  M. Trabucchi,et al.  Gender differences and health status in old and very old patients. , 2009, Journal of the American Medical Directors Association.

[22]  J. Wyka,et al.  Nutritional determination of the health status in polish elderly people from an urban environment , 2009, The journal of nutrition, health & aging.

[23]  E. Hummers-Pradier,et al.  Prevalence and predictors of polypharmacy among older primary care patients in Germany. , 2006, Family practice.

[24]  X. Cheng,et al.  Underuse of Medications for Chronic Diseases in the Oldest of Community‐Dwelling Older Frail Japanese , 2006, Journal of the American Geriatrics Society.

[25]  L. V. Van Bortel,et al.  PHARMACOTHERAPY OF DEPRESSION IN OLD AGE , 2005, Acta clinica Belgica.

[26]  M. Tinetti,et al.  The Relationship Between Number of Medications and Weight Loss or Impaired Balance in Older Adults , 2004, Journal of the American Geriatrics Society.

[27]  G. Pickering Frail elderly, nutritional status and drugs. , 2004, Archives of gerontology and geriatrics.

[28]  M. Dimatteo,et al.  Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. , 2000, Archives of internal medicine.

[29]  F. Haaijer-Ruskamp,et al.  Adverse drug reactions and polypharmacy in the elderly in general practice , 1999, European Journal of Clinical Pharmacology.

[30]  E. Steinhagen-Thiessen,et al.  Polypharmacy as a Risk Factor for Clinically Relevant Sarcopenia: Results From the Berlin Aging Study II , 2017, The journals of gerontology. Series A, Biological sciences and medical sciences.